1209781-11-2

Basic information

• Product Name: tert-butyl 3-(aMinoMethyl)-3-fluoropiperidine-1-carboxylate
• Synonyms: tert-butyl 3-(aMinoMethyl)-3-fluoropiperidine-1-carboxylate;3-FLUORO-3-HYDROXYMETHYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-Boc-3-fluoropiperidine-3-Methanol;tert-Butyl 3-fluoro-3-(hydroxymethyl)piperidine-1-carboxylate
• CAS NO: 1209781-11-2
• Molecular Formula: C11H21FN2O2
• Molecular Weight: 232.2950432
• Mol File: 1209781-11-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 3-(aMinoMethyl)-3-fluoropiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 3-(aMinoMethyl)-3-fluoropiperidine-1-carboxylate(1209781-11-2)
• EPA Substance Registry System: tert-butyl 3-(aMinoMethyl)-3-fluoropiperidine-1-carboxylate(1209781-11-2)

Safety Data

• Hazardous Substances Data: 1209781-11-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 3-(aminomethyl)-3-fluoropiperidine-1-carboxylate is used as an intermediate in the synthesis of pharmaceutical compounds. Its unique structure and properties make it a valuable building block for the development of new drugs, particularly in the areas of central nervous system disorders and pain management.
Used in Chemical Research:
In the field of chemical research, tert-butyl 3-(aminomethyl)-3-fluoropiperidine-1-carboxylate serves as a versatile compound for studying various chemical reactions and mechanisms. The steric hindrance provided by the tert-butyl group allows researchers to explore its effects on reaction rates, selectivity, and product formation, contributing to a deeper understanding of organic chemistry principles.
Used in Drug Development:
Tert-butyl 3-(aminomethyl)-3-fluoropiperidine-1-carboxylate is used as a key component in the development of new drugs, particularly for the treatment of neurological disorders and pain conditions. Its unique structure and properties enable the design of novel drug candidates with improved efficacy, selectivity, and safety profiles.
Used in Organic Synthesis:
As a white solid that is soluble in organic solvents, tert-butyl 3-(aminomethyl)-3-fluoropiperidine-1-carboxylate is utilized in various organic synthesis processes. Its reactivity and properties make it a suitable candidate for the preparation of a wide range of organic compounds, including pharmaceuticals, agrochemicals, and specialty chemicals.

Upstream product

• 148672-74-6 ethyl N-(t-butyloxycarbonyl)nipecotate 
• 1228631-45-5 (±)-1-tert-butyl 3-ethyl 3-fluoropiperidine-1,3-dicarboxylate 
• 934342-39-9 1-(tert-butoxycarbonyl)-3-fluoropiperidine-3-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1345456-33-8 ethyl (3S)-3-fluoro-2-oxo-3-piperidinecarboxylate 
• 1345459-64-4 (1S,2R,5S)-5-methyl-2-(1-methylethyl)cyclohexyl(3S)-3-fluoro-2-oxo-3-piperidinecarboxylate 
• 1345459-39-3 (1S,2R,5S)-5-methyl-2-(1-methylethyl)cyclohexyl 2-oxo-3-piperidinecarboxylate 
• 3731-16-6 3-carboethoxy-2-pyridone 

Downstream Products

• 1400586-21-1 7-[3,4-bis(methyloxy)phenyl]-N-{[(3S)-3-fluoro-3-piperidinyl]methyl}pyrido[3,4-b]pyrazin-5-amine hydrochloride 

Relevant articles and documents

PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS

The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.

BENZO[B]FURANS AS BROMODOMAIN INHIBITORS

The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.

1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES

The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

Asymmetric Fluorination Approach to the Scalable Synthesis of a SYK Inhibitor

A large-scale process for the synthesis of SYK inhibitor 1 has been developed and used to deliver multi-kilogram yields of this active pharmaceutical ingredient. Integral to the scalable process is a combined chiral auxiliary and chiral catalyst mediated

PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS

A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, and autoimmune conditions.

7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS

The present invention relates to a compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast and/or basophil cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, chronic spontaneous urticaria and autoimmune conditions.

PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS

A compound of formula (I) or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, and autoimmune conditions.

7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS

A compound of formula (I) or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast and/or basophil cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, chronic spontaneous urticaria and autoimmune conditions.